Use of vitamin K2 (menatetrenone) and 1,25-dihydroxyvitamin D3 in the prevention of bone loss induced by leuprolide

What Was Tested

This randomized controlled trial paper looks at Vitamin D, K2, Magnesium and Zinc and Leuprolide.

One hundred ten women (mean age, 46.2+/-0.5 yr), receiving leuprolide therapy for estrogen-dependent diseases (such as endometriosis and uterine leiomyomas), were randomly allocated into four groups (group A, leuprolide only; group B, leuprolide with vitamin K2; group C, leuprolide with 1,25-(OH)2D3; and group D, leuprolide with vitamin K2 and 1,25-(OH)2D3).

Bone formation and resorption markers were also measured before and after 6 months of treatment.

Who Took Part

The age groups tagged for this paper are adults and middle-aged adults, women only.

Bone mineral density of the lumbar spine was measured by dual-energy x-ray absorptiometry before and after 6 months of treatment.

How the Study Was Run

In design terms this was a randomized study.

The participants were allocated by chance, so the Vitamin D, K2, Magnesium and Zinc group and the comparison group should start out alike.

The methods mention a period of 6 months.

What Was Measured

Bone formation and resorption markers were also measured before and after 6 months of treatment.

The subject headings attached to it are Bone Density, Bone Resorption, Calcitriol, Leuprolide, Vitamin K and Vitamin K 2.

What This Means in Plain Language

The paper is a randomized study of Vitamin D, K2, Magnesium and Zinc and Leuprolide over 6 months.

The publication is from 1999 (The Journal of clinical endocrinology and metabolism), a journal based in United States.

More context: the Vitamin D, K2, Magnesium and Zinc compound page and the Leuprolide compound page, all human trials.